# Prongs or mask for nasal continuous positive airway pressure (CPAP) in preterm infants

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
21/07/2009		☐ Protocol		
Registration date 02/09/2009	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
05/11/2012	Respiratory			

## Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Colm O'Donnell

#### Contact details

Department of Neonatology
The National Maternity Hospital
Holles Street
Dublin
Ireland
2
+353 (0)1 637 3100
codonnell@nmh.ie

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

IRL/09/01

# Study information

#### Scientific Title

Nasal prongs versus nasal mask for continuous positive airways pressure (CPAP) in preterm infants: a randomised controlled trial

#### Acronym

The POM trial

#### **Study objectives**

Giving nasal continuous positive airway pressure (CPAP) to preterm infants with prongs is more effective than with a nasal mask.

#### Ethics approval required

Old ethics approval format

# Ethics approval(s)

Research and Ethics Committee of the National Maternity Hospital, Holles Street, Dublin, Ireland approved on the 14th July 2009

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

# Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

# Health condition(s) or problem(s) studied

Respiratory distress of newborn

#### Interventions

Infants starting nasal continuous positive airway pressure (CPAP) using either the Infant Flow Driver or Infant flow SiPAP machine (both made by Viasys Healthcare, Yorba Linda CA, USA) in the neonatal intensive care unit (NICU) will be randomised to receive CPAP with either short binasal prongs or nasal mask of appropriate size. Infants will receive CPAP with the randomly assigned interface for the duration of CPAP treatment, which will be determined by the care givers. Infants will be followed up until death or hospital discharge.

## Intervention Type

Other

#### **Phase**

Not Applicable

#### Primary outcome measure

Intubation and mechanical ventilation less than or equal to 72 hours of starting treatment, indicated by at least two of the five criteria:

- 1. Worsening clinical respiratory distress
- 2. Recurrent apnoeic episodes
- 3. Oxygen requirement greater than 40% to keep oxygen saturations greater than 85% for greater than 30 minutes
- 4. pH less than 7.2 on two blood gases at least 30 minutes apart
- 5. Carbon dioxide (PCO2) greater than 9kPa on two blood gases at least 30 minutes apart

#### Secondary outcome measures

- 1. Use of nasal intermittent positive pressure ventilation (NIPPV), measured at death or hospital discharge
- 2. Duration of NIPPV (days), measured at death or hospital discharge
- 3. Number of intubations, measured at death or hospital discharge
- 4. Doses of surfactant given, measured at death or hospital discharge
- 5. Duration of mechanical ventilation (in days and hours), measured at death or hospital discharge
- 6. Duration of CPAP (in days and hours), measured at death or hospital discharge
- 7. Duration of oxygen therapy (days), measured at death or hospital discharge
- 8. Oxygen therapy at 28 days
- 9. Oxygen therapy at 36 weeks' post-menstrual age
- 10. Highest persistent oxygen requirement on CPAP, measured at death or hospital discharge
- 11. Home oxygen therapy, measured at hospital discharge
- 12. Air leaks, measured at death or hospital discharge
- 13. Use of diuretics, measured at death or hospital discharge
- 14. Duration of diuretic therapy, measured at death or hospital discharge
- 15. Sepsis (blood, urine or cerebrospinal fluid culture positivity), measured at death or hospital discharge
- 16. Medical treatment for patent ductus arteriosus, measured at death or hospital discharge
- 17. Ligation of patent ductus arteriosus, measured at death or hospital discharge
- 18. Time to 120 ml/kg/day enteral feeds, measured at death or hospital discharge
- 19. Gastrointestinal perforation, measured at death or hospital discharge
- 20. Necrotising enterocolitis, measured at death or hospital discharge
- 21. Intraventricular haemorrhage, measured at death or hospital discharge
- 22. Periventricular leukomalacia, measured at death or hospital discharge
- 23. Retinopathy of prematurity, measured at death or hospital discharge
- 24. Duration of hospital stay (days), measured at death or hospital discharge
- 25. Death before discharge and at latest follow-up

#### Overall study start date

22/07/2009

#### Completion date

31/12/2010

# **Eligibility**

#### Key inclusion criteria

1. Infants born less than or equal to 30 weeks' gestation by best obstetric estimate, either sex 2. Receive nasal CPAP using the Infant Flow Driver or SiPAP machine (Viasys, Yorba Linda CA, USA) in the neonatal intensive care unit

# Participant type(s)

Patient

#### Age group

Neonate

#### Sex

Both

# Target number of participants

120

# Key exclusion criteria

Infants with congenital anomalies

#### Date of first enrolment

22/07/2009

#### Date of final enrolment

31/12/2010

# Locations

#### Countries of recruitment

Ireland

# Study participating centre Department of Neonatology

Dublin Ireland 2

# Sponsor information

#### Organisation

The National Children's Research Centre (Ireland)

# Sponsor details

Our Lady's Children's Hospital Crumlin Dublin Ireland 12 cblanco@nmh.ie

# Sponsor type

Research organisation

#### Website

http://www.childrensresearchcentre.org/index.html

#### **ROR**

https://ror.org/025qedy81

# Funder(s)

# Funder type

Hospital/treatment centre

#### Funder Name

Our Lady's Children's Hospital (Ireland) - The Childrens Research Centre

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2012		Yes	No